Ask AI
ProCE Banner Activity

HER2CLIMB-05: Tucatinib vs Placebo Added to Trastuzumab + Pertuzumab as First-line Maintenance Therapy for HER2+ MBC

Conference Coverage
Slideset

In this phase III trial in patients with HER2-positive metastatic breast cancer, adding tucatinib to first-line maintenance therapy with trastuzumab and pertuzumab significantly increased PFS compared with trastuzumab and pertuzumab alone.

Released: December 19, 2025

Share

Provided by

Provided by Clinical Care Options, LLC dba Decera Clinical Education

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, Gilead Sciences, Inc., Lilly, Novartis Pharmaceuticals Corporation, and Stemline Therapeutics, Inc.

AstraZeneca

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

Gilead Sciences, Inc.

Lilly

Novartis Pharmaceuticals Corporation

Stemline Therapeutics, Inc.

Target Audience

This activity is intended for oncologists and other healthcare professionals who care for patients with breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Identify subpopulations of patients with breast cancer most likely to benefit from a specific treatment plan based on predictive biomarkers

  • Apply recently presented data to clinical practice to expand treatment options and improve outcomes for patients with breast cancer
  • Evaluate new data on novel agents and therapeutic approaches for patients with breast cancer